Latest news with #US-only
Engadget
6 days ago
- Business
- Engadget
Nikon joins other camera manufacturers in raising prices due to tariffs
Nikon has announced that it will increase prices on its photography products in the US due to tariffs, joining other camera manufacturers including Canon, Blackmagic Design and Leica in doing so. It hasn't yet shared which products will be affected, but several outlets have received word from dealers that the changes will mostly affect lenses and accessories manufactured in China. "Due to the recent tariffs, a necessary price adjustment for products will take effect on June 23, 2025," the company wrote last week. "We will be carefully monitoring any tariff developments and may adjust pricing as necessary to reflect the evolving market conditions. We wish to thank our customers for their understanding and know that we are taking every possible step to minimize the impact on our community." The development comes from Trump's recent tariffs affecting electronic goods, with Nikon noting that the increase could cut its operating profit by around $68 million. Canon, the worldwide leader in camera sales, said in its earnings report last month that it would raise prices soon. Fujifilm recently paused US preorders for several models including the X-M5 and X100 VI. Other electronics companies, including Acer and DJI, also recently announced US-only price hikes. In its latest earnings report, Sony said it expects to seller fewer PS5s and expects a $700 million tariff-related revenue hit. These increases could just be the beginning. Nikon builds its products in multiple countries affected by US tariffs, including China, Thailand and its home country, Japan. Unless those nations can negotiate new tariff terms before the end of Trump's 90-day pause, they could be subject to drastically higher rates by July — which would in turn prices for Nikon and many other camera manufacturers.
&w=3840&q=100)
Business Standard
22-05-2025
- Business
- Business Standard
Stay in US funds if horizon exceeds seven years, exposure less than 20%
If you are worried about a US-only exposure following the downgrade of US government debt, go for a globally diversified fund Sanjay Kumar Singh Karthik Jerome New Delhi Listen to This Article Moody's Investors Service downgraded the United States (US) government's credit rating from AAA to AA1 on May 16, 2025. This has sparked concern among Indian retail investors who have diversified globally, with many questioning whether to maintain, reduce, or exit their US fund holdings. Why the downgrade happened The downgrade stems from the US's widening fiscal deficit and elevated debt-to-GDP ratio. 'The high level of debt-to-GDP ratio could make it difficult for the US to service its debt,' says Pratik Oswal, chief of passive business, Motilal Oswal Asset Management Company (AMC).
Kuwait Times
21-05-2025
- Business
- Kuwait Times
Global retailers may spread tariff pain by raising prices outside US
LONDON/FRANKFURT: Global retailers including sandal maker Birkenstock and jeweler Pandora are looking at spreading the cost of US tariffs by raising prices across markets to avoid big hikes in the United States that could hurt sales. A global presence gives large retailers an advantage to minimize higher tariff costs in the US. But it is putting central banks on watch as the strategy could fuel inflation in other markets like the European Union and Britain, where consumer prices have finally started to stabilize. Birkenstock's chief financial officer said last week that a 'low-single-digit' price increase globally would be enough to offset the US tariff impact. Pandora CEO Alexander Lacik said the Danish company is debating whether to raise prices globally or more in the US, its biggest market. 'Companies are really thinking about distributing the tariff,' said Markus Goller, partner at consultancy Simon Kucher in Bonn, Germany. 'A manufacturer from outside of the US might say, OK, I cannot increase my prices to the US market that much, so I will do a little increase in the US, and a little increase in Europe, and in other markets.' US President Donald Trump has imposed a blanket tariff of 10 percent on all global imports and is threatening higher so-called 'reciprocal' tariffs on its trading partners. When US behemoth Walmart said it would have to raise prices in response to tariffs, Trump ordered the world's biggest retailer via social media to 'eat the tariffs'. Announcing price increases in non-US markets could be a way for retailers to avoid a similar backlash from Trump. 'Obviously if your products coming into the US are now subject to tariffs, then math says that you have to raise your prices in the US,' said Jean-Pierre Dubé, professor of marketing at the University of Chicago Booth School of Business. 'But you don't want to be accused by the White House of raising prices purely because of US tariffs, so if you can demonstrate that your prices are going up everywhere then... it's kind of a shield.' Retailers could raise prices on certain products or in certain markets where consumers are less price-sensitive, and use that to subsidize other products or countries where price hikes would hurt sales more, said Jason Miller, professor of supply chain management at Michigan State University. 'Maybe a US-only firm has to raise (US) prices by 12 percent. But you, as a global firm, raise prices by 8 percent because you can play with pricing in other markets,' he said. If many multinational retailers do spread the tariff pain, higher inflation could spread even to countries which, like Britain, have already struck trade agreements with the US in a bid to minimize the economic fallout of tariffs. Bank of England Governor Andrew Bailey earlier this month raised the issue of 'global companies that don't make that distinction [on tariff rates] and just say, we're going to impose a pricing solution which goes right across the world irrespective of those differences.' 'I think we do have to watch that carefully,' he said. In the eurozone, inflation was finally gliding towards the European Central Bank's 2 percent target. European companies surveyed by the European Central Bank (ECB) in late March said price growth in the retail sector was subdued. But that was before Trump unveiled his tariff policy on April 2, and later hiked tariffs on Chinese goods to 145 percent. However, the US tariffs on China - lowered last week to 30 percent - have allowed some European retailers to source goods more cheaply than before. Martino Pessina, CEO of Takko Fashion, which sells clothes in 17 European countries, said suppliers in China had offered lower prices as US retailers cancelled orders from factories there, and shipping costs also fell. 'What we don't know is if there's going to be inflation in the US and if that inflation comes to Europe or not,' Pessina said. Some big retailers have in any case ruled out raising prices outside the US. 'There is no reason to raise prices outside the U.S. because of the tariffs,' Adidas CEO Bjorn Gulden told investors after reporting results late last month. 'The discussion we're having on tariffs is only for the US.' ECB executive board member Isabel Schnabel has said the euro zone's inflation rate may initially dip below the central bank's 2 percent target, but that tariffs might prove inflationary further down the road. While every company has its own pricing strategy, economists warn some could take advantage of tariffs to raise prices by more than rising costs, boosting their profits similarly to the inflation surge of 2021-2022 during the pandemic. -- Reuters
Business of Fashion
20-05-2025
- Business
- Business of Fashion
Global Retailers' Tariff Strategy Risks Spreading Pain Beyond US Consumer
Global retailers including sandal maker Birkenstock and jeweller Pandora are looking at spreading the cost of US tariffs by raising prices across markets to avoid big hikes in the United States that could hurt sales. A global presence gives large retailers an advantage to minimise higher tariff costs in the US, but it is putting central banks on watch as the strategy could fuel inflation in other markets like the European Union and Britain, where consumer prices have finally started to stabilise. Birkenstock's chief financial officer said last week that a 'low-single-digit' price increase globally would be enough to offset the US tariff impact. Pandora CEO Alexander Lacik said the Danish company is debating whether to raise prices globally or more in the US, its biggest market. 'Companies are really thinking about distributing the tariff,' said Markus Goller, partner at consultancy Simon Kucher in Bonn, Germany. 'A manufacturer from outside of the US might say, OK, I cannot increase my prices to the US market that much, so I will do a little increase in the US, and a little increase in Europe, and in other markets.' US President Donald Trump has imposed a blanket tariff of 10 percent on all global imports and is threatening higher so-called 'reciprocal' tariffs on its trading partners. When US behemoth Walmart said it would have to raise prices in response to tariffs, Trump ordered the world's biggest retailer via social media to 'eat the tariffs'. Announcing price increases in non-US markets could be a way for retailers to avoid a similar backlash from Trump. 'Obviously if your products coming into the US are now subject to tariffs, then math says that you have to raise your prices in the US,' said Jean-Pierre Dubé, professor of marketing at the University of Chicago Booth School of Business. 'But you don't want to be accused by the White House of raising prices purely because of US tariffs, so if you can demonstrate that your prices are going up everywhere then... it's kind of a shield.' Retailers could raise prices on certain products or in certain markets where consumers are less price-sensitive, and use that to subsidise other products or countries where price hikes would hurt sales more, said Jason Miller, professor of supply chain management at Michigan State University. 'Maybe a US-only firm has to raise (US) prices by 12 percent. But you, as a global firm, raise prices by 8 percent because you can play with pricing in other markets,' he said. If many multinational retailers do spread the tariff pain, higher inflation could spread even to countries which, like Britain, have already struck trade agreements with the US in a bid to minimise the economic fallout of tariffs. Bank of England governor Andrew Bailey earlier this month raised the issue of 'global companies that don't make that distinction [on tariff rates] and just say, we're going to impose a pricing solution which goes right across the world irrespective of those differences.' 'I think we do have to watch that carefully,' he said. Inflation Uncertainty In the euro zone, inflation was finally gliding towards the European Central Bank's 2 percent target. European companies surveyed by the European Central Bank (ECB) in late March said price growth in the retail sector was subdued. But that was before Trump unveiled his tariff policy on April 2, and later hiked tariffs on Chinese goods to 145 percent. However, the US tariffs on China - lowered last week to 30 percent - have allowed some European retailers to source goods more cheaply than before. Martino Pessina, CEO of Takko Fashion, which sells clothes in 17 European countries, said suppliers in China had offered lower prices as US retailers cancelled orders from factories there, and shipping costs also fell. 'What we don't know is if there's going to be inflation in the US and if that inflation comes to Europe or not,' Pessina said. Some big retailers have in any case ruled out raising prices outside the US. 'There is no reason to raise prices outside the US because of the tariffs,' Adidas CEO Bjorn Gulden told investors after reporting results late last month. 'The discussion we're having on tariffs is only for the US.' ECB executive board member Isabel Schnabel has said the euro zone's inflation rate may initially dip below the central bank's 2 percent target, but that tariffs might prove inflationary further down the road. 'In order to compensate for the hit to input costs, firms also tend to raise the prices of goods not directly affected by tariffs,' Schnabel said in a speech earlier this month. While every company has its own pricing strategy, economists warn some could take advantage of tariffs to raise prices by more than rising costs, boosting their profits similarly to the inflation surge of 2021-2022 during the pandemic. 'It will be very difficult for a firm's customers to know what portion of the product's total costs are subject to the tariff, or even the tariff rate that applies. This information asymmetry creates a ripe environment for exploitation. Just as it did during COVID,' said Hal Singer, professor of economics at the University of Utah. US consumers' 12-month inflation expectations jumped in April to 6.7 percent, the highest reading since 1981. And in the euro zone, too, consumers are expecting inflation to rise. 'If people are expecting inflation, well then it gives firms a little bit more room to raise prices,' said Miller. By Helen Reid, Francesco Canepa, Balazs Koranyi; Editors: Lisa Jucca and Susan Fenton
Yahoo
14-05-2025
- Business
- Yahoo
Lexicon Pharmaceuticals Inc (LXRX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ...
Release Date: May 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) announced an exclusive license agreement with Novo Nordisk for LX 9,851, potentially generating up to $1 billion in milestone payments and tiered royalties. The company identified a well-tolerated dose for Pillovapidin in its Phase 2B study, paving the way for Phase 3 trials. Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) successfully reduced operating costs and improved its balance sheet by utilizing upfront payments to reduce debt. The Sonata HCM study for sotocoflozin is progressing well, with all Phase 3 sites expected to be operational by Q3 2025. The company ended Q1 2025 with $194.8 million in cash and short-term investments, providing a strong financial position for future developments. Net loss for Q1 2025 was $25.3 million, although reduced from the previous year, it still indicates financial challenges. Research and development expenses increased to $15.3 million, reflecting higher costs associated with late-stage development programs. Revenue from MPEFA sales was limited, with minimal promotional activity impacting potential growth. The company faces significant competition in the HCM market, with other companies also targeting this space. There is uncertainty regarding the FDA's feedback on the Phase 3 trial designs for Pillovapidin, which could impact future development timelines. Warning! GuruFocus has detected 3 Warning Signs with LXRX. Q: Can you discuss the intended trial designs for the pain program and whether it makes sense to conduct three studies instead of two? A: Craig Granowitz, Chief Medical Officer, explained that the plan is to run two parallel trials with similar designs. One trial will be US-only, and the other will be worldwide, including US and non-US sites. Each trial will have about 300-350 patients per arm, testing a 10 mg dose versus placebo. They believe the clinical signal is robust and do not see the need for a third trial unless advised by the FDA. Q: Assuming the phase 2 goes well, when would the phase 3 pain data sets be available, and what additional studies are needed for an NDA filing? A: Craig Granowitz mentioned that addiction liability studies, likely in animal models, and additional metabolism studies are necessary. They are also validating renal clearance levels. Long-term CARC studies and preclinical trials are planned. They are confident in their manufacturing process and expect FDA feedback to guide any additional requirements. Q: How are the IND enabling studies for LX 9,851 progressing, and how involved is Novo Nordisk in this stage? A: Mike Eton, CEO, stated that the IND enabling studies are on track to finish this year. Novo Nordisk is highly engaged and collaborative, with direct access to data outputs. The studies are expected to conclude this year, after which Novo will submit the IND. Q: With recent updates in the HCM space, including the failed Odyssey trial, how does this affect your strategy for Soda in non-obstructive HCM? A: Mike Eton expressed confidence in Soda's potential for both obstructive and non-obstructive HCM. The Sonata trial is powered to see effects in both groups, and they do not plan to increase sample sizes. The trial design allows for rapid enrollment, and they believe Soda can be a significant treatment option. Q: Regarding the Sonata study, how are you ensuring a homogeneous population for non-obstructive HCM, and what are the inclusion criteria? A: Craig Granowitz explained that the trial focuses on symptomatic disease, reflecting diastolic dysfunction, a key aspect of HCM. They are confident in their HEFA results and believe non-obstructive HCM is a subset of HEFA. The trial design aims to capture a broad patient population, and they have confidence in the efficacy of Soda in this group. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
